Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M. W., Reinhard, F., Zhang, C. C., Shipitsin, M. V., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,839

Epithelial–mesenchymal transitions in tumour progression

Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767

Involvement of chemokine receptors in breast cancer metastasis

Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340

Complex networks orchestrate epithelial–mesenchymal transitions

Thiery, J. P., & Sleeman, J. P. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1835 · Cited by 3,947

Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis

Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R., Côme, C., Savagner, P., Gitelman, I., Richardson, A. L., & Weinberg, R. A. (2004) · Cell · doi:10.1016/j.cell.2004.06.006 · Cited by 3,917

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppé, J., Tong, F. K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,224

Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?

Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121

Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells.

PETERSEN, O. W., Rønnov‐Jessen, L., Howlett, A. R., & Bissell, M. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9064 · Cited by 1,096

Cancer Metastasis Is Accelerated through Immunosuppression during Snail-Induced EMT of Cancer Cells

Kudo‐Saito, C., Shirako, H., Takeuchi, T., & Kawakami, Y. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.023 · Cited by 872

The GAS6-AXL signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion

Zdżalik-Bielecka, D., Poświata, A., Kozik, K., Jastrzębski, K., Schink, K. O., Brewińska‐Olchowik, M., Piwocka, K., Stenmark, H., & Miączyńska, M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024596118 · Cited by 103

Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics

Zhang, J., Hu, Z., Horta, C. A., & Yang, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.002 · Cited by 106

Activation of TYRO3/AXL Tyrosine Kinase Receptors in Thyroid Cancer

Avilla, E., Guarino, V., Visciano, C., Liotti, F., Svelto, M., Krishnamoorthy, G., Franco, R., & Melillo, R. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2186 · Cited by 103

Tristability in Cancer-Associated MicroRNA-TF Chimera Toggle Switch

Lu, M., Jolly, M. K., Gomoto, R., Huang, B., Onuchic, J. N., & Ben‐Jacob, E. (2013) · The Journal of Physical Chemistry B · doi:10.1021/jp403156m · Cited by 102

TAM family kinases as therapeutic targets at the interface of cancer and immunity

DeRyckere, D., Huelse, J. M., Earp, H. S., & Graham, D. K. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00813-7 · Cited by 99

Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity

Davra, V., Kumar, S., Geng, K., Calianese, D. C., Mehta, D., Gadiyar, V., Kasikara, C., Lahey, K. C., Chang, Y., Wichroski, M. J., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2066 · Cited by 96

AXL signaling in cancer: from molecular insights to targeted therapies

Yadav, M., Sharma, A., Patne, K., Tabasum, S., Suryavanshi, J., Rawat, L., Machaalani, M., Eid, M., Singh, R. P., Choueiri, T. K., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02121-7 · Cited by 99

Role of microRNAs in the Regulation of Breast Cancer Stem Cells

Liu, S., Clouthier, S. G., & Wicha, M. S. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9242-8 · Cited by 96

Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis

Gao, Q., Yuan, Y., Gan, H., & PENG, Q. (2015) · Oncology Letters · doi:10.3892/ol.2015.2988 · Cited by 95

AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells

Lotsberg, M. L., Wnuk-Lipińska, K., Terry, S., Tan, T. Z., Lü, N., Trachsel-Moncho, L., Røsland, G. V., Siraji, M. I., Hellesøy, M., Rayford, A. J., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.015 · Cited by 95

Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer

Tanaka, M., & Siemann, D. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189953 · Cited by 94

Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review)

Luqmani (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.942 · Cited by 98

Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition

Engelsen, A. S. T., Lotsberg, M. L., Khouzam, R. A., Thiery, J. P., Lorens, J. B., Chouaı̈b, S., & Terry, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.869676 · Cited by 95

The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma

Hector, A., Montgomery, E. A., Karikari, C. A., Canto, M. I., Dunbar, K. B., Wang, J. S., Feldmann, G., Hong, S., Haffner, M. C., Meeker, A. K., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.10.13248 · Cited by 90

The diverse roles of glutathione-associated cell resistance against hypericin photodynamic therapy

Theodossiou, T. A., Olsen, C. E., Jonsson, M., Kubin, A., Hothersall, J. S., & Berg, K. (2017) · Redox Biology · doi:10.1016/j.redox.2017.02.018 · Cited by 88

Higher Expression of Receptor Tyrosine Kinase Axl, and Differential Expression of its Ligand, Gas6, Predict Poor Survival in Lung Adenocarcinoma Patients

Ishikawa, M., Sonobe, M., Nakayama, E., Kobayashi, M., Kikuchi, R., Kitamura, J., Imamura, N., & Date, H. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2795-3 · Cited by 93

Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma

Tworkoski, K., Singhal, G., Szpakowski, S., Zito, C. I., Bacchiocchi, A., Muthusamy, V., Bosenberg, M., Krauthammer, M. O., Halaban, R., & Stern, D. F. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0512 · Cited by 89

Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma

Kashyap, M. K., & Abdel-Rahman, O. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0790-4 · Cited by 87

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer Cells

Namba, K., Shien, K., Takahashi, Y., Torigoe, H., Sato, H., Yoshioka, T., Takeda, T., Kurihara, E., Ogoshi, Y., Yamamoto, H., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0628 · Cited by 86

ΔNp63α Promotes Breast Cancer Cell Motility through the Selective Activation of Components of the Epithelial-to-Mesenchymal Transition Program

Dang, T. T., Esparza, M. A., Maine, E. A., Westcott, J. M., & Pearson, G. W. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3363 · Cited by 85

In vivo animal models for studying brain metastasis: value and limitations

Daphu, I., Sundstrøm, T., Horn, S. A., Huszthy, P. C., Niclou, S. P., Sakariassen, P. Ø., Immervoll, H., Miletić, H., Bjerkvig, R., & Thorsen, F. A. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9566-9 · Cited by 84

Epithelial–Mesenchymal Plasticity in Tumor Immune Evasion

Mullins, R. D. Z., Pal, A., Barrett, T. F., Neal, M. E. H., & Puram, S. V. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4370 · Cited by 84

Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors

Feneyrolles, C., Spenlinhauer, A., Guiet, L., Fauvel, B., Daydé-Cazals, B., Warnault, P., Chevé, G., & Yasri, A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1083 · Cited by 83

Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl

Paccez, J. D., Duncan, K., Sekar, D., Correa, R. G., Wang, Y., Gu, X., Bashin, M., Chibale, K., Libermann, T. A., & Zerbini, L. F. (2019) · Oncogenesis · doi:10.1038/s41389-019-0122-6 · Cited by 81

TAM Receptor Inhibition–Implications for Cancer and the Immune System

Aehnlich, P., Powell, R., Peeters, M. J. W., Rahbech, A., & Straten, P. T. (2021) · Cancers · doi:10.3390/cancers13061195 · Cited by 84

The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications

Wium, M., Ajayi-Smith, A. F., Paccez, J. D., & Zerbini, L. F. (2021) · Cancers · doi:10.3390/cancers13071521 · Cited by 81

Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years

Haaland, G. S., Falk, R. S., Straume, O., & Lorens, J. B. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.5512 · Cited by 80

Polarization of tumor-associated macrophages and Gas6/Axl signaling in oral squamous cell carcinoma

Chiu, K., Lee, C.-H., Liu, S.-Y., Chou, Y., Huang, R., Huang, S., & Shieh, Y. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.04.004 · Cited by 81

AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis

Goyette, M.-A., & Côté, J. (2022) · Cancers · doi:10.3390/cancers14030466 · Cited by 80

CD44 Staining of Cancer Stem-Like Cells Is Influenced by Down-Regulation of CD44 Variant Isoforms and Up-Regulation of the Standard CD44 Isoform in the Population of Cells That Have Undergone Epithelial-to-Mesenchymal Transition

Biddle, A., Gammon, L., Fazil, B., & Mackenzie, I. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057314 · Cited by 79

Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer

Wang, Y., Xia, H., Zhuang, Z., Miao, L., Chen, X., & Cai, H. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.186 · Cited by 77

Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models

Kanlikilicer, P., Özpolat, B., Aslan, B., Bayraktar, R., Gürbüz, N., Rodriguez‐Aguayo, C., Bayraktar, E., Denizli, M., González-Villasana, V., Ivan, C., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.06.023 · Cited by 77

Homing of Cancer Cells to the Bone

Mishra, A., Shiozawa, Y., Pienta, K. J., & Taichman, R. S. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0083-6 · Cited by 76

Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy

Gu, Y., Zhang, Z., & ten Dijke, P. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-00980-8 · Cited by 78

Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma

Yu, H., Liu, R., Ma, B., Li, X., Yen, H.-Y., Zhou, Y., Krasnoperov, V. G., Xia, Z., Zhang, X., Bove, A. M., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.237 · Cited by 77

The receptor tyrosine kinase Axl regulates cell–cell adhesion and stemness in cutaneous squamous cell carcinoma

Cichoń, M. A., Szentpétery, Z., Caley, M. P., Papadakis, E. S., Mackenzie, I. C., Brennan, C. H., & O’Toole, E. A. (2013) · Oncogene · doi:10.1038/onc.2013.388 · Cited by 75

Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases

Toll, A., Masferrer, E., Hernández-Ruiz, M.-B., Ferrándiz‐Pulido, C., Yébenes, M., Jaka, A., Tuneu, A., Jucglá, A., Gimeno, J., Baró, T., et al. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.07.001 · Cited by 75

Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance

D’Errico, G., Alonso‐Nocelo, M., Vallespinós, M., Hermann, P. C., Alcalá, S., Pedrero, C., Martín-Hijano, L., Valle, S., Earl, J., Cassiano, C., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0803-9 · Cited by 75

Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis

Cronan, M. R., Nakamura, K., Johnson, N. L., Granger, D. A., Cuevas, B. D., Wang, J.-G., Mackman, N., Scott, J. E., Dohlman, H. G., & Johnson, G. L. (2011) · Oncogene · doi:10.1038/onc.2011.544 · Cited by 74

Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors

Sinha, S., Boysen, J. C., Nelson, M., Secreto, C. R., Warner, S. L., Bearss, D. J., Lesnick, C. E., Shanafelt, T. D., Kay, N. E., & Ghosh, A. K. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1892 · Cited by 75

ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer

Guo, Q., Grimmig, T., González, G., Giobbie‐Hurder, A., Berg, G., Carr, N., Wilson, B. J., Banerjee, P., Ma, J., Gold, J. S., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003187 · Cited by 74

Axl Phosphorylates Elmo Scaffold Proteins To Promote Rac Activation and Cell Invasion

Abu-Thuraia, A., Gauthier, R., Chidiac, R., Fukui, Y., Screaton, R. A., Gratton, J., & Côté, J. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00764-14 · Cited by 74

Targeting epithelial–mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring

Bhatia, S., Monkman, J. H., Toh, A. K. L., Nagaraj, S. H., & Thompson, E. W. (2017) · Biochemical Journal · doi:10.1042/bcj20160782 · Cited by 76

TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling

Roberts, C. M., Tran, M. A., Pitruzzello, M. C., Wen, W. X., Loeza, J., Dellinger, T. H., Mor, G., & Glackin, C. A. (2016) · Scientific Reports · doi:10.1038/srep37652 · Cited by 72

Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment

Pandey, N., Anastasiadis, P., Carney, C. P., Kanvinde, P. P., Woodworth, G. F., Winkles, J. A., & Kim, A. J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114415 · Cited by 74

Heterogeneity of expression of epithelial–mesenchymal transition markers in melanocytes and melanoma cell lines

Kim, J. E., Leung, E. Y., Baguley, B. C., & Finlay, G. J. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00097 · Cited by 72

Distinct roles of AKT isoforms in regulating β1-integrin activity, migration, and invasion in prostate cancer

Virtakoivu, R., Pellinen, T. S., Rantala, J., Perälä, M., & Ivaska, J. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-03-0213 · Cited by 71

Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays

Gujral, T. S., Karp, R. L., Finski, A., Chan, M. M., Schwartz, P. E., MacBeath, G., & Sorger, P. K. (2012) · Oncogene · doi:10.1038/onc.2012.378 · Cited by 71

Targeting TYRO3 inhibits epithelial–mesenchymal transition and increases drug sensitivity in colon cancer

Chien, C.-W., Hou, P.-C., Wu, H.-C., Chang, Y.-L., Lin, S.-C., Lin, S.-C., Lin, B.-W., Lee, J.-C., Chang, Y.-J., Sun, H. S., et al. (2016) · Oncogene · doi:10.1038/onc.2016.120 · Cited by 71

Axl inhibitors as novel cancer therapeutic agents

Shen, Y., Chen, X., He, J., Liao, D., & Zu, X. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.02.033 · Cited by 72

AXL as a Target in Breast Cancer Therapy

Colavito, S. A. (2020) · Journal of Oncology · doi:10.1155/2020/5291952 · Cited by 70

Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response

Davra, V., Kimani, S. G., Calianese, D. C., & Birge, R. B. (2016) · Cancers · doi:10.3390/cancers8120107 · Cited by 74

The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase

Gajiwala, K. S., Grodsky, N. B., Bolaños, B., Feng, J., Ferre, R. A., Timofeevski, S. L., Xu, M., Murray, B. W., Johnson, T. W., & Stewart, A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.771485 · Cited by 70

Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention

Antony, J., Thiery, J. P., & Huang, R. Y. (2019) · Physical Biology · doi:10.1088/1478-3975/ab157a · Cited by 70

The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview

Wium, M., Paccez, J. D., & Zerbini, L. F. (2018) · Cells · doi:10.3390/cells7100166 · Cited by 73

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

Røsland, G. V., Dyrstad, S. E., Tusubira, D., Helwa, R., Tan, T. Z., Lotsberg, M. L., Pettersen, I. K. N., Berg, A., Kindt, C. K., Hoel, F., et al. (2019) · Cancer & Metabolism · doi:10.1186/s40170-019-0197-8 · Cited by 69

Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma

Johnson, C. E., Gorringe, K. L., Thompson, E. R., Opeskin, K., Boyle, S. E., Wang, Y.-K., Hill, P., Mann, G. B., & Campbell, I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1835-1 · Cited by 67

Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways

Wu, X., Zahari, M. S., Ma, B., Liu, R., Renuse, S., Sahasrabuddhe, N. A., Chen, L., Chaerkady, R., Kim, M., Zhong, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5020 · Cited by 66

AXL is an oncotarget in human colorectal cancer

Martinelli, E., Martini, G., Cardone, C., Troiani, T., Liguori, G., Vitagliano, D., Napolitano, S., Morgillo, F., Rinaldi, B., Melillo, R. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3962 · Cited by 66

The role of epithelial plasticity in prostate cancer dissemination and treatment resistance

Bitting, R. L., Schaeffer, D., Somarelli, J. A., García-Blanco, M. A., & Armstrong, A. J. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9483-z · Cited by 66

Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels

Goyette, M.-A., Elkholi, I. E., Apcher, C., Kuasne, H., Rothlin, C. V., Muller, W. J., Richard, D. E., Park, M., Gratton, J., & Côté, J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023868118 · Cited by 64

Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology

Rogers, A., Le, J., Sather, S., Pernu, B. M., Graham, D. K., Pierce, A. M., & Keating, A. K. (2011) · Oncogene · doi:10.1038/onc.2011.588 · Cited by 64

Implications of Hypoxia in Breast Cancer Metastasis to Bone

Gilkes, D. M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101669 · Cited by 65

Axl Is a Prognostic Marker in Oral Squamous Cell Carcinoma

Lee, C., Yen, C.-Y., Liu, S.-Y., Chen, C.-K., Chiang, C., Shiah, S., Chen, P.-H., & Shieh, Y. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1985-8 · Cited by 62

Axl Receptor Blockade Ameliorates Pulmonary Pathology Resulting from Primary Viral Infection and Viral Exacerbation of Asthma

Shibata, T., Habiel, D. M., Coelho, A. L., Kunkel, S. L., Lukacs, N. W., & Hogaboam, C. M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302766 · Cited by 63

4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors

Tan, L., Zhang, Z., Gao, D., Luo, J., Tu, Z., Li, Z., Peng, L., Ren, X., & Ding, K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00608 · Cited by 61

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients

Bottai, G., Raschioni, C., Székely, B., Tommaso, L. D., Szász, A. M., Losurdo, A., Győrffy, B., Ács, B., Torrisi, R., Karachaliou, N., et al. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.33 · Cited by 61

Epigenetic Silencing of TAP1 in Aldefluor+ Breast Cancer Stem Cells Contributes to Their Enhanced Immune Evasion

Sultan, M., Vidovic, D., Paine, A. S., Huynh, T. T., Coyle, K. M., Thomas, M. L., Cruickshank, B. M., Dean, C. A., Clements, D. R., Kim, Y., et al. (2018) · Stem Cells · doi:10.1002/stem.2780 · Cited by 60

S100A14 regulates the invasive potential of oral squamous cell carcinoma derived cell-lines in vitro by modulating expression of matrix metalloproteinases, MMP1 and MMP9

Sapkota, D., Bruland, O., Costea, D. E., Haugen, H., Vasstrand, E. N., & Ibrahim, S. O. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.012 · Cited by 59

Axl receptor tyrosine kinase expression in breast cancer

D’Alfonso, T. M., Hannah, J., Chen, Z., Liu, Y., Zhou, P., & Shin, S. J. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-202161 · Cited by 59

Mesenchymal-Epithelial Transition and Circulating Tumor Cells in Small Cell Lung Cancer

Hamilton, G., & Rath, B. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55947-6_12 · Cited by 59

High-Dimensional Phenotyping Identifies Age-Emergent Cells in Human Mammary Epithelia

Pelissier Vatter, F. A., Schapiro, D., Chang, H., Borowsky, A. D., Lee, J. K., Parvin, B., Stampfer, M. R., LaBarge, M. A., Bodenmiller, B., & Lorens, J. B. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.114 · Cited by 58

The Gas6/TAM System and Multiple Sclerosis

Bellan, M., Pirisi, M., & Sainaghi, P. P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111807 · Cited by 58

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

Adam‐Artigues, A., Arenas, E. J., Martínez, A., Brasó‐Maristany, F., Cervera, R., Tormo, E., Hernándo, C., Martínez, M. T., Carbonell‐Asins, J. A., Simón, S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abk2746 · Cited by 57

Efficient in vivo vascularization of tissue-engineering scaffolds

Hegen, A., Blois, A. L., Tiron, C. E., Hellesøy, M., Micklem, D., Nor, J. E., Akslen, L. A., & Lorens, J. B. (2010) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.336 · Cited by 57

Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation

Wei, C., & Li, X. (2020) · BMC Cancer · doi:10.1186/s12885-020-07555-0 · Cited by 60

The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges

Sang, Y. B., Kim, J.-H., Kim, C.-G., Hong, M. H., Kim, H. R., Cho, B. C., & Lim, S. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.811247 · Cited by 56

Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update

Ahsan, A. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24223-1_7 · Cited by 56

Signaling pathways and mesenchymal transition in pediatric high-grade glioma

Meel, M. H., Schaper, S. A., Kaspers, G. J. L., & Hulleman, E. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2714-7 · Cited by 58

Simultaneous Integration of Multi-omics Data Improves the Identification of Cancer Driver Modules

Silverbush, D., Cristea, S., Arad, G., Geiger, T., Beerenwinkel, N., & Sharan, R. (2019) · Cell Systems · doi:10.1016/j.cels.2019.04.005 · Cited by 56

ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling

Wang, J., Rouse, C., Jasper, J. S., & Pendergast, A. M. (2016) · Science Signaling · doi:10.1126/scisignal.aad3210 · Cited by 55

All-in-One digital microfluidics pipeline for proteomic sample preparation and analysis

Peng, J., Chan, C. C. H., Zhang, S., Sklavounos, A. A., Olson, M. E., Scott, E., Hu, Y., Rajesh, V., Li, B. ‘., Chamberlain, M. D., et al. (2023) · Chemical Science · doi:10.1039/d3sc00560g · Cited by 57

Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer

Nalwoga, H., Ahmed, L., Arnes, J. B., Wabinga, H., & Akslen, L. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146823 · Cited by 55

Endometrial Stromal and Epithelial Cells Exhibit Unique Aberrant Molecular Defects in Patients With Endometriosis

Logan, P. C., Yango, P., & Tran, N. D. (2017) · Reproductive Sciences · doi:10.1177/1933719117704905 · Cited by 54

Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer

Kyriakopoulou, K., Kefali, E., Piperigkou, Z., Bassiony, H., & Karamanos, N. K. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.07.010 · Cited by 54

Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma

Li, Y., Li, J., Ren, D., Liu, C., Gong, Y., Wang, N., Zhang, X., & Zhao, Y. (2014) · IUBMB Life · doi:10.1002/iub.1285 · Cited by 52

The AXL Receptor Is a Sensor of Ligand Spatial Heterogeneity

Meyer, A. S., Zweemer, A. J. M., & Lauffenburger, D. A. (2015) · Cell Systems · doi:10.1016/j.cels.2015.06.002 · Cited by 54

Cisplatin influences acquisition of resistance to molecular‐targeted agents through epithelial–mesenchymal transition‐like changes

Kurokawa, M., Ise, N., Omi, K., Goishi, K., & Higashiyama, S. (2013) · Cancer Science · doi:10.1111/cas.12171 · Cited by 52

Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase

Ott, M., Litzenburger, U. M., Sahm, F., Rauschenbach, K. J., Tudoran, R., Hartmann, C. J., Márquez, V. E., von Deimling, A., Wick, W., & Platten, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047663 · Cited by 55

PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration

Chiappetta, G., Valentino, T., Vitiello, M., Pasquinelli, R., Monaco, M., Palma, G., Sepe, R., Luciano, A., Pallante, P., Palmieri, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2776 · Cited by 52

Racial Variation in Breast Tumor Promoter Methylation in the Carolina Breast Cancer Study

Conway, K., Edmiston, S. N., Tse, C., Bryant, C., Kuan, P. F., Hair, B. Y., Parrish, E., May, R., & Swift‐Scanlan, T. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-1228 · Cited by 52

ΔNp63α induces the expression of FAT2 and Slug to promote tumor invasion

Dang, T. T., Westcott, J. M., Maine, E. A., Kanchwala, M., Xing, C., & Pearson, G. W. (2016) · Oncotarget · doi:10.18632/oncotarget.8696 · Cited by 53

The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma

Hsieh, M., Yang, P., Wong, L.-F., & Lee, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9231 · Cited by 52

Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer

Quinn, J. M., Greenwade, M. M., Palisoul, M. L., Opara, G., Massad, K., Guo, L., Zhao, P., Beck-Noia, H., Hagemann, I. S., Hagemann, A. R., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0537 · Cited by 52

Ribosomal Protein S6 Kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein

Ma, Q., Guin, S., Padhye, S., Zhou, Y.-Q., Zhang, R., & Wang, M. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-66 · Cited by 51

Multicenter analysis of soluble A xl reveals diagnostic value for very early stage hepatocellular carcinoma

Reichl, P., Fang, M., Starlinger, P. P., Staufer, K., Nenutil, R., Müller, P., Greplová, K., Valík, D., Dooley, S., Brostjan, C., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29394 · Cited by 50

Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma

Liu, J., Wang, K., Yan, Z., Xia, Y., Li, J., Shi, L., Zou, Q., Wan, X., Jiao, B., Wang, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154767 · Cited by 50

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma

Pinato, D. J., Brown, M., Trousil, S., Aboagye, E. O., Beaumont, J., Zhang, H., Coley, H. M., Mauri, F. A., & Sharma, R. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0373-6 · Cited by 50

Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma

Bae, C. A., Ham, I., Oh, H. J., Lee, D., Woo, J., Son, S., Yoon, J. H., Lorens, J. B., Brekken, R. A., Kim, T., et al. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01066-4 · Cited by 50

AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew

Auyez, A., Sayan, E., Kriajevska, M. V., & Tulchinsky, E. M. (2021) · Cancers · doi:10.3390/cancers13194864 · Cited by 50

Abstract B105: Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

Gjerdrum, C., Tiron, C. E., Høiby, T., Stefansson, I. M., Haugen, H., Sandal, T., Collet, K., Li, S., McCormack, E., Gjertsen, B. T., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-09-b105 · Cited by 1

Abstract 3308: Axl is required for EMT-induced stem cell traits and metastasis in breast cancer

Tiron, C. E., Stefansson, I. M., Haugen, H., Sandal, T., McCormack, E., Gjertsen, B. T., Micklem, D., Ivaska, J., Akslen, L. A., & Lorens, J. B. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-3308

Abstract C76: Axl signaling is required for stem cell traits and metastasis in breast cancer

Tiron, C. E., Pelissier, F. A., Wnuk-Lipińska, K., Stefansson, I. M., Virtakoivu, R., Miyano, M., Sandal, T., Micklem, D., Garbe, J. C., Stampfer, M. R., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.tim2013-c76

Abstract 4888: Axl receptor signaling in required for stem cell traits and metastasis in breast cancer.

Tiron, C. E., Pelissier, F. A., Wnuk-Lipińska, K., Stefansson, I. M., Virtakoivu, R., Miyano, M., Sandal, T., Micklem, D., Garbe, J. C., Stampfer, M. R., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-4888

The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression

Goyette, M.-A., Duhamel, S., Aubert, L., Pelletier, A., Savage, P., Thibault, M.-P., Johnson, R. M., Carmeliet, P., Basik, M., Gaboury, L. A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.019 · Cited by 148